China Should Focus On APIs And Pharmaceutical Preparations - CPEA Chairman
This article was originally published in PharmAsia News
Executive Summary
The China Pharmaceutical Enterprises Association's Chairman Yu Mingde remarked that China's pharmaceutical industry should focus on developing both APIs and pharmaceutical preparations
You may also be interested in...
China To Fund API Makers To Promote Exports
SHANGHAI - The Chinese government will spend RMB 5 billion ($760 million) to upgrade drug manufacturing quality assurance in an effort to help active pharmaceutical ingredient makers comply with global good manufacturing practices so they can export to the U.S. and Europe, an unnamed government official told the Shanghai Securities News
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.